For patients with advanced non-small-cell lung cancer (NSCLC) without targetable oncogene alterations (EGFR, ALK, ROS-1, etc.), chemotherapy used to be the best first-line treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.